Clinical Trials and Research News Weekly Roundup | Ivermectin Moves Towards Mainstream

TrialSite News Ivermectin

Ivermectin Moves Towards Mainstream: Recently, the National Institutes of Health (NIH) got around to formally addressing ivermectin in their COVID-19 Treatment Guidelines. Although their only recommendation is for use in clinical trials, that’s a start. TrialSite has been working tirelessly to chronicle and accumulate data centering on the off-label use, case series, observational and randomized clinical trial information possibly pointing to the future acceptance of this cheap and available drug as but one possible contributing way to help fight COVID-19. TrialSite has reported that in at least three randomized clinical trials (Egypt, Bangladesh, and Iraq), the use of the drug targeting early-stage COVID-19 patients leads to positive results; in addition to several observational and hospital approved case series efforts, TrialSite applauds the nation’s research institution for at least taking the time to acknowledge and review the recent Broward County study led by Dr. Jean Jacques Rajter. The apparent fact that this generic drug, which costs about $7 per pill in the US, may be useful as a treatment to alleviate symptoms of...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee